WE CLAIM:

1. A compound according to formula I

I 

wherein R1 = -H, -CN, -COO+, -COS+, -COOH, -COSH, -COOR1.1, -COSR1.1, N-phthalimidyl,

wherein R1.1 = -H, Cl-10 alkyl, C1-10 aralkyl or aryl,

wherein R2 = -H, C1-C4 alkyl, -OR1.1, -Hal (-F -Cl, -Br, -J), -NR2.1R2.2, -Am, -O-Am, -S-Am,

wherein R3 = -H, C1-C4 alkyl, -OR1.1, -Hal (-F -Cl, -Br, -J), -NR2.1R2.2, -Am, -O-Am, -S-Am,

wherein R2.1 = -H, Cl-10 alkyl, C1-10 aralkyl or aryl,

wherein R2.2 = -H, Cl-10 alkyl, C1-10 aralkyl or aryl,

wherein R2.1 and R2.2 may be identical or different,

wherein n and m may be identical or different and 0 to 10,

wherein o and p may be identical or different and 0 to 3,

wherein o > 0, if n and m = 0,

wherein R2 and R3 may be identical or different for Cn and/or Cm,

wherein R2 may be identical or different for every Cx = 1 ... n,

wherein R3 may be identical or different for every Cy = 1 ... m,

wherein -Am is an amino acid radical,

wherein q and r = 0 or 1 and identical or different,

wherein $-O_r-$ and/or $-O_q-$ may also be replaced by $-S_r-$ or $-S_q-$, resp.,

wherein -NR2.1R2.2 may be replaced by a linear or branched -C1-C20 alkyl, aralkyl or aryl,

wherein a group -CN, -(CO)-CN, -(CO)-O-R1 or -(CO)-R1 or -C-O-R1 may be replaced by $-SO_2-NR2.1R2.2$,

or a physiologically well tolerated salt of such a compound.

2. A compound according to claim 1, wherein R1 = -CN.

3. A compound according to claim 1 or 2, wherein at least one of the R2 comprises -Am, wherein -Am preferably represents an amino acid radical of an essential amino acid, wherein in particular q = 0 and r = 1 or q = 1 and r = 0 or q = 1 and r = 1, m = 1, R3 = -H, n = o = p = 0, R2.1 = R2.2 = -H.

4. A compound according to claim 1 or 2, wherein n = o = p = 0, wherein m = 0 to 4, wherein R2 = R3 = -H, or for at least one R2, R2= - Am, wherein R2.1 = R2.2 = -H, wherein q = 0 and r = 1.

5. A compound according to claim 1 or 2, wherein m = p = 0, wherein o = 1, wherein n = 0 to 4, wherein R2 = H, or for at least one R2, R2= - Am, wherein R3 = -H or -Hal in the case Cx = 1, wherein R3 = -H for all Cx = n > 1, wherein R2.1 = R2.2 = -H, wherein q = 0 and r = 1.

6. A compound according to claim 1 or 2, wherein m = 1 to 4, wherein n = o = p = 0, wherein R2 = H, or for at least one R2, R2= - Am, wherein R3 = -H or -Hal in the case Cy = 1, wherein R3 = -H for all Cy = m > 1, wherein R2.1 = R2.2 = -H, wherein q = 0 and r = 1.

7. A compound according to claim 1 or 2, wherein o = p = 1, wherein m = 0, wherein n = 0 to 4, wherein R2 = R3 = -H, or for at least one R2, R2= - Am, wherein R2.1 = R2.2 = -H, wherein q = 0 and r = 1.

8. A compound according to claim 1 or 2, wherein n = p = 0, wherein o = 1, wherein m = 0 to 4, wherein R2 = R3 = -H, or for at least one R2, R2= - Am, wherein R2.1 = R2.2 = -H, wherein q = 0 and r = 1.

9. A compound according to claim 1 or 2, wherein m = p = 0, wherein o = 1, wherein n = 1 to 4, wherein R2 = R3 = -H, or for at least one R2, R2= - Am, wherein R2.1 = R2.2 = -H, wherein q = 0 and r = 1.

10. Cancelled

11. A method for treating one or several diseases from the group comprising cancer, chronic inflammations, asthma, arthritis, osteoarthritis, chronic polyarthritis, rheumatic arthritis, inflammatory bowl disease, degenerative joint diseases, rheumatic diseases with cartilage disorders, sepsis, autoimmune diseases, type I diabetes, Hashimoto thyreoiditis, autoimmune thrombocytopenia, multiple sclerosis, myasthenia gravis, chronically inflammatory intestinal diseases, Crohn's disease, uveitis, psoriasis, collagenoses, Goodpasture syndrome, diseases with disturbed leukocyte adhesion, cachexia, diseases by increased TNF-alpha concentration, diabetes, adiposity, bacterial infections including those by antibiotic resistant bacteria comprising administering a pharmaceutical composition prepared comprising the compound according to Claim 1.

12. A pharmaceutical composition, wherein a compound according to Claim 1 is mixed with one or several physiologically well tolerated auxiliary substances and/or carrier substances and galenically prepared for local oral, or systemic administration comprising intravenous administration.

13. A method for inhibiting in vivo glycolysis or glutaminolysis of pyruvate kinase, asparaginase, serine dehydratases, transaminases, glutamate oxalacetate transaminase, glutamate pyruvate transaminase, glutamate dehydrogenase, malate dehydrogenase, desaminases or

glutaminases in prokaryotes or eukaryotes comprising administering a pharmaceutical composition comprising the compound according to Claim 1.